Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ)

The Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ) is a reliable and valid patient-oriented measure of the adverse effects of heart failure on a patient's life.
Technology No. 94019

The United States Food and Drug Administration (FDA) has approved the Minnesota Living with Heart Failure Questionnaire as Medical Device Development Tool (MDDT) for use in controlled clinical trials designed to test superiority or non-inferiority of medical devices in support of regulatory submissions. The patient-reported outcomes can be used to determine whether a treatment for heart failure is effective for improving patients’ quality of life by reducing the adverse impact of heart failure.

License Required to use MLHFQ

A license from the University of Minnesota is required to use MLHFQ for any purpose. Purchase the license that best matches your intended use.   Questionnaire (version 3) and supporting materials available for download after online completion of license agreement and payment of fee.

MLHFQ Translations

The Questionnaire is available from the University of Minnesota in the English language version only.

The MLHFQ license allows you to translate the Questionnaire without any further obligations to the University of Minnesota as long as all translations are used for the same study or protocol.  Additional information on obtaining translations.

Quality of Life Questionnaire - Scoring Criteria

The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient’s life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses.

The instrument can be used as a key outcome measure in studies and evaluations of outpatients with symptomatic (NYHA class II to IV) heart failure with a reduced or preserved ejection fraction. This patient-reported outcome can be used to determine whether a treatment for heart failure is effective for improving patients’ quality of life by reducing the adverse impact of heart failure.

MLHFQ Detailed Information

More detailed information about the Minnesota Living with Heart Failure Questionnaire is available in the FDA MDDT Qualification Package. A license from the University of Minnesota is required before using the Questionnaire.

Researchers: Dr. Thomas Rector & Dr. Jay Cohn

Please send your inquiries to mlhfq@umn.edu

  • swap_vertical_circlelibrary_booksReferences (0)
  • swap_vertical_circlecloud_downloadDownloads (1)
    *
    MLHFQ Package.zip
    size: 407 KB, type: application/zip
    Files marked with an asterix (*) can only be downloaded by users that have the appropriate product license. The license must be active and you must be logged into your account.
MLHFQ - Commercial Product Evaluation License

Term: 10 years

Price: $3,000.00 excl. VAT

MLHFQ - Instructional or Student Use License

Term: perpetual

Price: $0.00 excl. VAT

MLHFQ - Non-Profit Research Projects License

Term: 10 years

Price: $1,000.00 excl. VAT

MLHFQ - Patient Care - Patient Care License

Term: 10 years

Price: $1,000.00 excl. VAT

MLHFQ - Unlimited Non-Profit Research Projects License

Term: 5 years

Price: $5,000.00 excl. VAT

MLHFQ - Unlimited Patient Care License

Term: 10 years

Price: $2,500.00 excl. VAT

MLHFQ - Unlimited Commercial Product Evaluation License

Term: 5 years

Price: $15,000.00 excl. VAT

Questions about this technology?